|
Art. 1
1 Patents for inventions are granted for new inventions applicable in industry. 2 Anything that is obvious having regard to the state of the art (Art. 7 para. 2) is not patentable as an invention.7 3 Patents are granted without the guarantee of the State.8 7Amended by Art. 2 of the FD of 16 Dec. 2005 on the approval of the Act revising the European Patent Convention and on the amendment of the Patents Act, in force since 13 Dec. 2007 (AS 2007 6479; BBl 2005 3773). 8Amended by No I of the FA of 17 Dec. 1976, in force since 1 Jan. 1978 (AS 1977 1997; BBl 1976 II 1).
|
Art. 1a9
1 The human body as such, at all stages of its formation and development, including the embryo, is not patentable. 2 Elements of the human body in their natural environment are not patentable. An element of the human body is, however, patentable as an invention if it is produced by means of a technical process, a beneficial technical effect is indicated and the further requirements of Article 1 are fulfilled; Article 2 remains reserved.
|
Art. 1b10
1 A naturally occurring sequence or partial sequence of a gene is not patentable as such. 2 Sequences that are derived from a naturally occurring sequence or partial sequence of a gene may, however, be patented as an invention if they are produced by means of a technical process, their function is specifically indicated, and the further requirements of Article 1 are fulfilled; Article 2 remains reserved.
|
Art. 211
1 Inventions whose exploitation is contrary to human dignity or that disregard the integrity of living organisms or that are in any other way contrary to public policy or morality are not patentable. In particular, no patent may be granted for: - a.
- processes for cloning human beings and the clones obtained thereby;
- b.
- processes for forming hybrid organisms by using human germ cells, human totipotent cells or human embryonic stem cells and the entities obtained thereby;
- c.
- processes of parthenogenesis by using human germinal material and the parthenogenetic entities obtained thereby;
- d.
- processes for modifying the germ line genetic identity of human beings and the germ line cells obtained thereby;
- e.
- unmodified human embryonic stem cells and stem cell lines;
- f.
- the use of human embryos for non-medical purposes;
- g.
- processes for modifying the genetic identity of animals which are likely to cause them suffering without being justified by overriding interests worthy of protection, and also animals resulting from such processes.
2 Also excluded from patentability are: - a.
- methods for treatment by surgery or therapy and diagnostic methods practised on the human or animal body;
- b.
- plant varieties and animal varieties or essentially biological processes for the production of plants or animals; however, subject to the reservation of paragraph 1, microbiological or other technical processes and the products obtained thereby as well as inventions that concern plants or animals are patentable provided that their application is not technically confined to a single plant or animal variety.
|
Art. 3
1 The inventor, his successor in title, or a third party owning the invention under any other title has the right to the grant of the patent. 2 Where several inventors have made an invention jointly, they have this right jointly. 3 Where two or more inventors have made the invention independently of each other, the person who makes the earlier application or whose application has the earliest priority date has this right.
|
Art. 4
In the procedure before the Swiss Federal Institute of Intellectual Property12 (IPI)13, the patent applicant is deemed entitled to request the grant of the patent. 12Name in accordance with No I of the FA of 9 Oct. 1998, in force since 1 May 1999 (AS 1999 1363; BBl 1998 1633). 13 Abbreviation in accordance with Annex No 3 of the FA of 21 June 2013, in force since 1 Jan. 2017 (AS 2015 3631; BBl 2009 8533).
|
Art. 5
1 The patent applicant must provide the IPI with written confirmation of the name of the inventor.14 2 The person named by the patent applicant shall be mentioned as the inventor in the Patent Register, in the publication of the patent application and in the grant of the patent, as well as in the patent specification.15 3 Paragraph 2 applies by analogy if a third party produces an enforceable judgment establishing that he and not the person named by the patent applicant is the inventor.
|
Art. 6
1 If the inventor named by the patent applicant waives his right to the measures provided for in Article 5 paragraph 2, these measures shall not be taken. 2 A declaration made beforehand by the inventor waiving the right to be mentioned as such has no legal effect.
|
Art. 716
1 An invention is considered to be new if it does not form part of the state of the art. 2 The state of the art comprises everything made available to the public by means of a written or oral description, by use, or in any other way prior to the filing or priority date. 3 With regard to novelty, the state of the art also includes the content of an earlier application or application with earlier priority designating Switzerland in the version originally filed, and with a filing or priority date that precedes the date mentioned in paragraph 2, and which was only made available to the public on or after that date, provided that: - a.
- in the case of an international application, the requirements of Article 138 are fulfilled;
- b.
- in the case of a European application based on an international application, the requirements of Article 153 paragraph 5 of the European Patent Convention of 5 October 1973 in its revised version of 29 November 200017 are fulfilled;
- c.
- in the case of a European application, the fees for the valid designation of Switzerland as per Article 79 paragraph 2 of the European Patent Convention of 5 October 1973 in its revised version of 29 November 2000 have been paid.18
|
|
Art. 7b20
Where the invention has been made available to the public in the six months prior to the application date or priority date, this disclosure does not form part of the state of the art when it is due to, or a consequence of:21 - a.
- an evident abuse in relation to the patent applicant or his legal predecessor; or
- b.
- the fact that the patent applicant or his legal predecessor has displayed the invention at an official or officially recognised international exhibition falling within the terms of the Convention on International Exhibitions of 22 November 192822, and he has declared the fact at the time of filing and has produced sufficient supporting evidence in due time.
|
Art. 7c23
Any substance or composition that forms part of the state of the art as such, but not in relation to its use in a surgical, therapeutic or diagnostic method specified in Article 2 paragraph 2 letter a24 is deemed to be new provided it is intended solely for such use.
|
Art. 7d25
Any substance or composition that forms part of the state of the art as such, but not in relation to a specific use in a surgical, therapeutic or diagnostic method specified in Article 2 paragraph 2 letter a26 that is distinct from the first medical use specified in Article 7c is deemed to be new provided it is intended for use in the manufacture of a means to a surgical, therapeutic or diagnostic end. 25Inserted by Art. 2 of the FD of 16 Dec. 2005 on the approval of the Act revising the European Patent Convention and on the amendment of the Patents Act (AS 2007 6479; BBl 2005 3773). Amended by No I of the FA of 22 June 2007, in force since 1 July 2008 (AS 2008 2551; BBl 2006 1). 26 Rectified by the Editorial Commission of the Federal Assembly (Art. 58 para. 1 ParlA – SR 171.10).
|
Art. 827
1 The patent confers on its proprietor the right to prohibit others from commercially using the invention. 2 Use includes, in particular, manufacturing, storage, offering, placing on the market, importing, exporting and carrying in transit, as well as possession for any of these purposes. 3 Carrying in transit may only be prohibited if the proprietor of the patent is permitted to prohibit importation into the country of destination.
|
Art. 8a28
1 If the invention concerns a manufacturing process, the effects of the patent also extend to the products directly obtained by that process. 2 If the products directly obtained by the process concern biological material, the effects of the patent also extend to products obtained by propagating the biological material and which demonstrate the same characteristics. Article 9a paragraph 3 remains reserved.29
|
Art. 8b30
If the invention concerns a product that consists of or contains genetic information, the effects of the patent extend to any material in which the product is incorporated and in which the genetic information is contained and performs its function. Article 1a paragraph 1 and 9a paragraph 3 remain reserved.31
|
Art. 8c32
The protection conferred by a claim to a nucleotide sequence that is derived from a naturally occurring sequence or partial sequence of a gene is limited to the sequence segments that perform the function specifically described in the patent.
|
Art. 933
1 The effects of the patent do not extend to: - a.
- acts undertaken within the private sphere for non-commercial purposes;
- b.
- acts undertaken for research or experimental purposes in order to obtain knowledge about the subject-matter of the invention including its uses; in particular, any scientific research concerning the subject-matter of the invention is permitted;
- c.
- acts necessary for obtaining marketing authorisation for a medicinal product in Switzerland or in countries with equivalent medicinal product control;
- d.
- the use of the invention for teaching purposes at educational institutions;
- e.
- the use of biological material for the purpose of the production or the discovery and development of a plant variety;
- f.
- biological material that is obtained in the field of agriculture due to chance or is technically unavoidable;
- g.34
- acts undertaken as part of a medical activity concerning an individual person or animal and involving a medicinal product, in particular the prescribing, dispensing or use of medicinal products by legally authorised persons;
- h.35
- the direct individual preparation of medicinal products in pharmacies in accordance with a doctor’s prescription or to acts concerning medicinal products prepared in this way.
2 Agreements which limit or revoke the powers contained in paragraph 1 are null and void.
|
Art. 9a36
1 If the proprietor of the patent has placed patent-protected goods on the market in Switzerland or within the European Economic Area, or consented to their placing on the market in Switzerland or within the European Economic Area, these goods may be imported and used or resold commercially in Switzerland. 2 If he has placed apparatus that can be used with a patent-protected process on the market in Switzerland or within the European Economic Area, or consented to its placing on the market in Switzerland or within the European Economic Area, the first and each subsequent person who acquires the apparatus is entitled to use this process. 3 If the proprietor of the patent has placed patent-protected biological material on the market in Switzerland or within the European Economic Area, or consented to its placing on the market in Switzerland or within the European Economic Area, this material may be imported and propagated in Switzerland, provided this is necessary for its intended use. The material so obtained may not be used for further propagation. Article 35a remains reserved. 4 If the proprietor of the patent has placed patent-protected goods on the market outside the European Economic Area or consented to their placing on the market outside the European Economic Area und if the patent protection for the functional characteristics of the goods is only of subordinate importance, the goods may be imported commercially. Subordinate importance is presumed unless the proprietor of the patent provides prima facie evidence to the contrary. 5 Irrespective of the provisions of paragraphs 1–4, the consent of the proprietor of the patent for the placing on the market of patent-protected goods is reserved if their price in Switzerland or in the country in which they are placed on the market is fixed by the state.
|
|
Art. 11
1 Products that are protected by a patent, or their packaging, may be marked as being patented with the Federal Cross and the number of the patent. The Federal Council may prescribe additional indications.38 2 The proprietor of the patent may require any prior user or any licensee to affix the patent mark on the products manufactured by them or on the packaging of such products. 3 If the prior user or licensee does not comply with the requirement of the proprietor of the patent, he is liable to the latter for any resulting losses without prejudice to the proprietor’s right to require the use of the patent mark.
|
Art. 12
1 Any person who issues or offers for sale his business papers, notices of any kind, products or goods bearing any other notice referring to patent protection must inform any third party on request of the number of the patent application or the patent to which the notice refers. 2 Any person who accuses third parties of infringing his rights or warns them against such infringement must, on request, give them the same information.
|
Art. 1339
1 Any person who is involved in administrative proceedings provided for in this Act and does not have a residence or principal place of business in Switzerland must designate an address for service in Switzerland unless international law or the competent foreign body permits the authority to serve documents directly in the state concerned.40. An address for service in Switzerland is not required for:41 - a.
- filing a patent application for the purpose of being accorded a filing date;
- b.
- paying fees, filing translations and filing and handling requests after the grant of the patent, in so far as the requests do not give rise to any objections.42
1bis The IPI is entitled to declare to the competent foreign body that direct service is permitted in Switzerland in intellectual property matters provided Switzerland is granted reciprocal rights.43 2 The provisions concerning the practice of the profession of attorney remain reserved. 39Amended by No I of the FA of 17 Dec. 1976, in force since 1 Sept. 1978 (AS 19771997; BBl 1976 II 1). 40 Amended by Annex No 4 of the FD of 28 Sept. 2018 on the Approval and Implementation of European Convention No 94 on the Service Abroad of Documents relating to Administrative Matters, in force since 1 April 2019 (AS 2019 975; BBl 2017 5947). 41 Amended by Annex No 3 of the Patent Attorney Act of 20 March 2009, in force since 1 July 2011 (AS 2011 2259; BBl 2008 407). 42 Amended by Art. 2 of the FD of 22 June 2007, in force since 1 July 2008 (AS 2008 2677; BBl 2006 1). 43 Inserted by Annex No 4 of the FD of 28 Sept. 2018 on the Approval and Implementation of European Convention No 94 on the Service Abroad of Documents relating to Administrative Matters, in force since 1 April 2019 (AS 2019 975; BBl 2017 5947).
|
Art. 14
1 The maximum term of the patent is 20 years from the filing date of the application.44 2 …45
|
Art. 15
1 The patent lapses: - a.
- if the proprietor surrenders it by written declaration to the IPI;
- b.
- if a renewal fee that has become due is not paid within the prescribed time.46
2 …47
|
Art. 1648
Patent applicants or proprietors who are Swiss nationals may rely on the provisions of the binding text for Switzerland of the Paris Convention for the Protection of Industrial Property of 20 March 1883,49 where those provisions are more favourable than the provisions of this Act.
|